The geroscience hypothesis focuses on extending the healthy lifespan by targeting aging mechanisms. Recent advances in ...

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have rapidly emerged as game-changers in treating diabetes, heart ...

Marks the first jurisdictional issuance of an international patent for a family of novel small molecule compounds. Patent ...

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in 2025.

VANCOUVER - In a significant development for its proprietary small molecule drug candidates, InMed Pharmaceuticals Inc.

Icelandic drug discovery and development company Arctic Therapeutics (ATx) today announced the successful closing of a ?26.5 million oversubscribed Series A financing from a broad syndicate ...

Computational research conducted by scientists from Washington University in St. Louis shows that GLP-1 agonists can have ...

Icelandic drug discovery and development company Arctic Therapeutics (ATx) today announced the successful closing of a €26.5 million oversubscribed Series A financing from a broad syndicate of ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

The DYRK1A enzyme is a pivotal contributor to frequent and severe episodes of otitis media in Down syndrome, positioning it as a promising target for therapeutic interventions.

Microglia, the brain’s immune cells, play vital roles in clearing toxins and maintaining neuronal health but can also ...

Axsome Therapeutics, Inc. , a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the ...